INTRODUCTION
============

Venoms from both vertebrate and invertebrate species represent a huge and essentially unexplored reservoir of bioactive components ([@CIT0002]) and recent advances in methodology, permitting characterization of these components from small quantities of material, has meant that venoms are becoming increasingly important in natural products-based drug discovery. The venom of the eastern African arboreal snake, the Eastern green mamba *Dendroaspis angusticeps* (Elapidae) has proved to be a rich source of peptides that have been used as molecular tools to study the physiology and pathophysiology of receptors and ion channels. These include toxins with high affinity and specificity for muscarinic acetylcholine receptor subtypes ([@CIT0011]) and for α1- and α2-adrenoreceptors ([@CIT0015]), as well as dendrotoxins that selectively block voltage-dependent potassium channels of the Kv1 subfamily ([@CIT0007]) and calcicludins that block L-type calcium channels ([@CIT0022]). In addition, green mamba venom contains a wide range of other biologically active compounds such as fasciculins that potently inhibit acetylcholinesterase ([@CIT0019]), and a natriuretic peptide (DNP) with greater potency and increased stability compared with ANP, BNP, and CNP from mammals ([@CIT0024]).

There is a constant need for new types of anti-cancer agents particularly in cases where the tumor is not responsive to conventional pharmaceutical therapy due to the development of drug resistance ([@CIT0014]). Because of their non-specific and destructive mechanism of action, a number of naturally occurring cytotoxic host-defense peptides in frog skin secretions have been shown to have therapeutic potential for development into anti-cancer agents ([@CIT0005]). The presence in venoms of peptides and proteins with cytotoxic activity against tumor cells has been described for a wide range of snake species, particularly those belonging to the Viperidae family \[reviewed in ([@CIT0008]; [@CIT0004]). There have been fewer studies *in vivo* involving peptides from elapid snakes but dendrotoxin-κ from black mamba venom ([@CIT0009]) and α-cobratoxin from the venom of the Thai cobra *Naja kaouthia* ([@CIT0006]) have been shown to suppress the growth of tumors induced by human non-small cell lung adenocarcinoma A549 cells in nude mice.

The aim of the present study was to analyse a venom sample from an elapid snake, the green mamba *D. angusticeps* for the presence of components with anti-tumor activity using A549 cells, breast adenocarcinoma MDA-MB-231 cells, and colorectal adenocarcinoma HT-29 cells. The cytotoxic activity against tumor cells was compared with hemolytic activity against human erythrocytes, cytotoxic activity against human umbilical vein endothelial HUVEC cells, and antimicrobial activity using reference strains of Gram-negative *Escherichia coli* and Gram-positive *Staphylococcus aureus* bacteria.

MATERIALS AND METHODS
=====================

Cytotoxicity assays
-------------------

Human non-small cell lung adenocarcinoma A549 cells were maintained at 37^o^C in RPMI 1640 medium containing 2mM L-glutamine and supplemented with 10% (v/v) fetal calf serum (FCS, Biowest, Nouaille, France), and antibiotics (penicillin 50U/ml; streptomycin 50µg/ml) ([@CIT0001]). Human breast adenocarcinoma MDA-MB-231 cells and human colorectal adenocarcinoma HT-29 cells were maintained in Dulbecco\'s Modified Eagle\'s Medium (DMEM) supplemented with antibiotics (penicillin 50U/ml; streptomycin 50μg/ml) and 10% (v/v) FCS ([@CIT0001]). EndoGRO human umbilical vein endothelial cells (HUVECs) were maintained in EndoGRO MV-VEGF Complete Media Kit (Millipore, Temecula, CA, USA) ([@CIT0004]). In all experiments, cell viability was higher than 99% using trypan blue dye exclusion. Cells were seeded in 96-well plates at a density of 5x10^3^ cells/well. After 24hrs, cells were treated for 24hrs with increasing concentrations of purified toxin F-VIII (1 - 300µg/ml) and toxin C13S1C1 (1--100µg/ml) in triplicate. The effect of the peptides on cell viability was determined by measurement of ATP concentrations using a CellTiter-Glo Luminescent Cell Viability assay (Promega Corporation, Madison, WI, USA). Luminescent signals were measured using a GLOMAX Luminometer system. The LC~50~ value, calculated by non-linear regression analysis using commercially available software (SPSS version 17.0; SPSS Inc, Chicago, IL, USA), was taken as the mean concentration of peptide producing 50% cell death in three independent experiments.

Hemolysis assay
---------------

The hemolytic activities of the purified peptides in the concentration range of 75--600μg/ml for toxin C13S1C1 and in the range 125--1000μg/ml for toxin F-VIII against washed human erythrocytes (2x10^7^ cells) from a healthy donor were determined as previously described ([@CIT0004]).

Antimicrobial assays
--------------------

The abilities of freeze-dried aliquots (100µl) of chromatographic effluent ([Figure 1](#F1){ref-type="fig"}) to inhibit the growth of reference strains of *E. coli* (ATCC 25726) and *S. aureus* (ATCC 25923) were determined in duplicate using 96-well microtiter cell-culture plates. After reconstitution in Mueller-Hinton broth (50μl), the fractions were incubated with an inoculum (50μl of 10^6^ colony forming units/ml) from a log-phase culture of the bacteria for 18hrs at 37^o^C in a humidified atmosphere of air. After incubation, the absorbance of each well was determined at 630nm using a microtiter plate reader. Minimum inhibitory concentrations (MICs) of the purified toxins against *S. aureus* and *E. coli* were measured in the concentration range of 6.25--200μg/ml by a standard double dilution method ([@CIT0003]).

![Reversed-phase HPLC on a preparative Vydac C-18 column of venom from *D.* *angusticeps*. The peaks designated 1, containing toxin F-VIII, and 2, containing toxin C13S1C1, displayed strong cytotoxic activity against lung adenocarcinoma A549 cells and were purified further. The dashed line shows the concentration of acetonitrile in the eluting solvent.](JVR-05-16-g001){#F1}

Purification of the cytotoxic peptides
--------------------------------------

Venom from *D. angusticeps* was purchased in lyophilized form from a commercial supplier (Jonathan Leakey Ltd, Nakuru, Kenya). The venom sample (432mg) was redissolved in 0.1% (v/v) trifluoroacetic acid(TFA)/water (4ml) and injected onto a (2.2cmx25cm) Vydac 218TP1022 (C-18) reversed-phase HPLC column (Grace, Deerfield, IL, USA) equilibrated with 0.1% (v/v) TFA/water at a flow rate of 6ml/min. The concentration of acetonitrile in the eluting solvent was raised to 21% (v/v) over 10min and to 63% (v/v) over 60min using linear gradients. Absorbance was monitored at 214nm and 280nm, and fractions (1min) were collected. Freeze-dried aliquots (100μl) of the fractions were reconstituted in RPMI 1640 medium (100μl) and their abilities to produce cytolysis of lung adenocarcinoma A549 cells were determined as described in the cytotoxicity assays section. Fractions containing peptides with cytotoxic activity were successively chromatographed on a (1cmx25cm) Vydac 214TP510 (C-4) column and a (1cmx25cm) Vydac 208TP510 (C-8) column at a flow rate of 2ml/min. The concentration of acetonitrile in the eluting solvent was raised from 21% to 42% over 60min for the purification of toxin F-VIII, and from 21% to 56% for the purification of toxin C13SIC1.

Identification of the cytotoxic peptides
----------------------------------------

The molecular masses of the purified peptides were determined by LC-MS using a nano-Acquity UltraPerformance LC (UPLC) with a BEH130 C18 (100µmx100mm, 1.7µm particle size) column in-line with a Waters SYNAPT G2 High Definition Mass Spectrometry System. The flow rate was set to 0.6µl/min and the column was eluted with a linear gradient of 0.1% (v/v) formic acid in water (solution A) and 0.1% (v/v) formic acid in acetonitrile (solution B), isocratically 1% B for 1min, followed by 1--12% B for 1min, 12--40% B for 15min, and 40--85% B for 2min.

The purified cytotoxic peptides were initially analyzed by SDS-PAGE on 15% (w/v) polyacrylamide gels under reducing and non-reducing conditions and the protein bands were excised from Coomassie Brilliant Blue-stained gels and subjected to automated reduction, alkylation, and in-gel digestion with sequencing grade porcine pancreatic trypsin using a Progest™ digestor (Genomic Solutions, Ann Arbor, MI, USA). The tryptic peptide mixtures in 15μl of 5% (v/v) acetonitrile containing 0.1% (v/v) formic acid were separated by nano-Acquity UltraPerformance LC using the same chromatographic conditions as described above for the purified parent molecules. Doubly and triply charged ions were selected for collision-induced dissociation (CID) MS/MS. Fragmentation spectra were interpreted manually (*de novo* sequencing) or processed in a Waters Corporation\'s ProteinLynx Global SERVER 2013 version 2.5.2. with Expression version 2.0 against the 81 *Dendroaspis* venom sequences retrieved from UniProtKB/Swiss-Prot (UniProt release 2014_02) and the non-redundant NCBI database (GenBank Release 200.0). MS/MS mass tolerance was set to ±0.6Da. Carbamidomethyl cysteine and oxidation of methionine were selected as fixed and variable modifications, respectively.

RESULTS
=======

Purification of the cytotoxic peptides
--------------------------------------

The elution profile on a preparative Vydac C-18 column of the venom from *D.* *angusticeps* is shown in [Figure 1](#F1){ref-type="fig"}. Under the conditions of assay, the prominent peaks designated 1 and 2 contained material with cytotoxic activity (\>98% cell death during a 24 h incubation) against human lung adenocarcinoma A549 cells. The results of SDS-PAGE of the peaks on 15% (w/v) polyacrylamide gels under reducing and non-reducing conditions are shown in [Figure 2](#F2){ref-type="fig"}. Studied at the same concentration, no fraction contained material that inhibited growth of *E. coli* and *S. aureus.* Purification to near homogeneity, as assessed by a symmetrical peak shape and mass spectrometry, of the components in peaks 1 and 2 was accomplished by chromatography on a semi-preparative Vydac C-8 column (data not shown). The yield of the purified peptide 1 (subsequently shown to be toxin F-VIII) was 12.2mg representing 2.8 % of the total mass of lyophilized venom. The final yield of pure peptide 2 (subsequently shown to be toxin C13S1C1) was 2.3mg representing 0.53 % of the total mass of lyophilized venom.

![SDS-PAGE on 15% (w/v) polyacrylamide gels under reducing and non-reducing conditions of the peptides in fractions 28, 29.1 (ascending limb), and 29.2 (descending limb) from [Figure 1](#F1){ref-type="fig"} containing toxin F-VIII and in fraction 43 from [Figure 1](#F1){ref-type="fig"} containing toxin C13S1C1. The gels were stained with Coomassie Brilliant Blue and the major bands excised for in-gel digestion with trypsin.](JVR-05-16-g002){#F2}

Identification of the cytotoxic peptides
----------------------------------------

The identities of the cytotoxic peptides were determined by CID-MS/MS mass spectrometric analysis of fragments generated by in-gel tryptic digestion. In the case of the peak 1 peptide, the following fragments were identified: MICYSHK, TPQPSATITCEEKTCYKK, TPQPSATITCEEKTCYK, TPQPSATITCEEK, SVRLPAIVAGR, GCGCPSKEMLVAIHCCR, and EMLVAIHCCR. The component was unambiguously identified as toxin F-VIII (UniProtKB/Swiss-Prot: P01404) and the complete primary structure is shown in [Figure 3](#F3){ref-type="fig"}. The C-terminal fragment SDKCNE was not identified, presumably because it was cleaved to SDK and CNE. The average molecular mass (\[M+H\]^+^) of the purified toxin F-VIII is consistent with its proposed structure: M~r~ obs 6597.8, M~r~ calc 6597.8. M~r~ obs refers to the observed molecular mass in Daltons and M~r~ calc refers to the molecular mass calculated from the proposed sequences shown in [Figure 3](#F3){ref-type="fig"}.

![A comparison of the primary structures of toxin F-VIII and toxin C13S1C1 from *D.* *angusticeps* venom. Amino acid residues in common are shaded.](JVR-05-16-g003){#F3}

In the case of the peak 2 peptide, the following fragments were identified: ICYSHKLLQAK, TTKTCEENSCYKR, SLPKIPLIIIGR, GCGCPLTLPFLR, IPLIIIGRGCGCPLTLPFLR, and IKCCTSDKCN. The component was unambiguously identified as toxin C13S1C1 (UniProtKB/Swiss-Prot: P18329) and the complete primary structure is shown in [Figure 3](#F3){ref-type="fig"}. The average molecular mass (\[M+H\]^+^) of the purified peptide is also consistent with its proposed structure: M~r~ obs 6653.0, M~r~ calc 6652.6.

Cytotoxic activities of the peptides
------------------------------------

Toxin C13S1C1 showed cytotoxic activity against human non-small cell lung adenocarcinoma A549 cells, breast adenocarcinoma MDA-MB-231 cells, colorectal adenocarcinoma HT-29 cells, and human umbilical vein endothelial HUVEC cells The LC~50~ values are shown in [Table 1](#T1){ref-type="table"}. The effect of increasing concentrations of the peptide on cell viability is shown in [Figure 4](#F4){ref-type="fig"}. A549 cells (LC~50~ = 56µg/ml; approx. 8 µM) and HUVEC cells (LC~50~ = 57µg/ml; approx. 8µM)) were the most sensitive to the cytotoxic action of the peptide and HT-29 cells the most resistant (LC~50~ = 110µg/ml; approximately 16µM). The amount of available pure peptide was insufficient to determine the LC~50~ value for toxin C13S1C1 against human erythrocytes but the peptide produced only 21% hemolysis after a 1hr incubation with a 600µg/ml concentration. Toxin C13S1C1 did not inhibit the growth of *E. coli* and *S. aureus* at concentrations up to 200μg/ml. In contrast, toxin F-VIII was active only against A549 cells LC~50~ = 106µg/ml (approximately 15µM) and did not produce significant cell death in either MDA-MB-231 cells or HT-29 cells at concentrations up to 300µg/ml during a 24hr incubation ([Table 1](#T1){ref-type="table"}). The peptide showed no hemolytic activity against human erythrocytes and no antimicrobial activity against *E. coli* and *S. aureus* at concentrations up to 1mg/ml*.*

###### 

Cytotoxicities of toxin C13S1C1 and toxin F-VIII against human non-small cell lung adenocarcinoma A549 cells, breast adenocarcinoma MDA-MB-231 cells, colorectal adenocarcinoma HT-29 cells, human umbilical vein endothelial HUVEC cells, and red blood cells (RBC)

                  **A549**   **MDA-MB-231**   **HT-29**   **HUVEC**   **RBC**
  --------------- ---------- ---------------- ----------- ----------- ---------
  Toxin C13S1C1   56±4       62±2             110±4       57±3        \>600
  Toxin F-VIII    106±5      \>300            \>300       \>300       \>1000

Data show LC~50~ values (μg/ml) ±SEM

![Effects of (A) toxin C13S1C1 and (E) toxin F-VIII on the viability of non-small cell lung adenocarcinoma A549 cells; (B) toxin C13S1C1 and (F) toxin F-VIII on the viability of breast adenocarcinoma MDA-MB-231 cells; (C) toxin C13S1C1 and (G) toxin F-VIII on the viability of colorectal adenocarcinoma HT-29 cells, and (D) toxin C13S1C1 and (H) toxin F-VIII on the viability of human umbilical vein endothelial HUVEC cells All experiments were repeated at least three times. Columns: mean; bars: SEM. ](JVR-05-16-g004){#F4}

DISCUSSION
==========

The present study has shown that, under the conditions of assay, toxin C13S1C1 is the component with the greatest cytotoxicity against three human tumor cell lines in the venom of the green mamba *D. angusticeps*. However, its therapeutic potential as an anti-tumor agent is restricted by appreciable cytotoxic activity against non-neoplastic HUVEC cells. A second component, toxin F-VIII was cytotoxic only against lung adenocarcinoma A549 cells. These peptides were first identified on the basis of relatively low toxicity in mice ([@CIT0010]) and ability to block voltage-dependent potassium channels ([@CIT0023]). As shown in [Figure 3](#F3){ref-type="fig"}, toxin C13S1C1 and toxin F-VIII are structurally related (48.6% amino acid sequence identity) and are members of the three-finger toxin (3FTx) superfamily ([@CIT0012]). Peptides in this family are characterized by three antiparallel β-sheet loops that are stabilized by four, or less commonly five, disulfide bridges. 3FTx peptides are not confined to the venoms of elapids (mambas, cobras, and kraits) but have also been identified the venoms of colubrids ([@CIT0018]), hydrophiids ([@CIT0017]) and vipers (Doley et al., 2008).

Several components in venoms from Viperidae have been shown to possess potent anti-bacterial and anti-fungal activity although the precise biological significance of this observation is unclear \[reviewed in ([@CIT0021]; [@CIT0004])\]. Among snakes belonging to the Elapidae, L-amino acid oxidases from the Central Asian cobra *Naja naja oxiana* venom ([@CIT0020]) and from the king cobra *Ophiophagus hannah* ([@CIT0013]) show broad-spectrum antibacterial activity whereas omwaprin from the venom of inland taipan *Oxyuranus microlepidotus* is active only against Gram-positive bacteria ([@CIT0016]). Cathelicidin-BF from the venom of the banded krait *Bungarus fasciatus* shows greatest activity against Gram-negative bacteria ([@CIT0025]). However, neither toxin F-VIII nor toxin C13S1C1 showed growth inhibitory activity against reference strains of the Gram-negative *E. coli* and the Gram-positive *S. aureus* at concentrations up to 200μg/ml.

CONCLUSION
==========

Toxin C13S1C1 shows broad-spectrum anti-tumor activity combined with low cytotoxicity to red blood cells. However, its therapeutic potential for development into an anti-cancer agent is low because of its lack of selectivity towards cell lines derived from neoplastic tissues.
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